(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3...c. (NYSE: CRY ),a biomaterials, medical device an...it is scheduled to participate in the 19th Annual ... Hotel in New York City on Tuesday,November 27, 20...Life, Inc. will deliver,the Company,s presentation...fe,s live presentation may be accessed through its...
...re/ - Cytochroma Inc. announced today,that it has ... CTAP101,Capsules, the Company,s product candidate...hronic kidney disease (CKD). This Phase I/II clin...ed to establish the pharmacokinetic profile and sa...D insufficiency. The product,s,pharmacokinetic pro...
... Third quarter Consolidated Net Income NIS 178 Mil...Quarter 2006 Results Adversely Affected by,Norther...raft Prospectus for the Issue of,Debentures Primar...tures,Were Rated AA Stable by Maalot, a Standard a...ORL) ("Oil Refineries" or the "Company"),announced...
Other Biology Technology:CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York 2Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease 2Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 2Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 3Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 4Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 5Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 6Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 7Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 8Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 9Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 10Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 11...Microarray is specifically designed for location a...ins by pairing chromatin immunoprecipitation (ChIP...robust hybridization and reliable binding data wit...tives. In addition, Agilent provides flexibility b...
...ore user-friendliness and absolute reliability uni...ion of the Mastercycler ep system. In the past few...ynamically. The same applies to the capabilities r...echnological advances, the challenges of tomorrow ...
...s-based research with S. aureus, Sigma-Genosys has...at contains PCR primers to amplify all open readin...rimer pairs are included to amplify ORFs that are ...eus. The ORFmer set contains primers to amplify al...
...Handler is a high-capacity, plug-and-play bench to...ers, readers and liquid handling systems together ...ibility and intuitive and powerful software. Wheth...nking several modules together to complete a robot...
Biology Products: